Drugs / Duodopa
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03419806 Comparator | Feb 2018 → Mar 2020 | Parkinson disease | Vastra Gotaland Region | Completed | No outcome recorded |
| — | NCT06432309 Background | Jul 2022 → Dec 2023 | Parkinson disease | University Hospital of Ferrara | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duodopa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03419806 ↗ |
| Known as | LCIG | “Levodopa-carbidopa intestinal gel (LCIG) - under the name of Duodopa® - is delivered directly to the proximal jejunum via a tube connected to a portable infusion pump.” NCT03419806 ↗ |
| Route | Other | “Levodopa carbidopa intestinal gel infusion.” NCT06432309 ↗ |